Physician profile
Herbert Vandenberg
NPI 1558397109
$5,385.61
in general payments reported to CMS, 2019-2025
24 companies · $911 in 2025
The $911 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $526 · 2021: $723 · 2022: $827 · 2023: $1,005 · 2024: $730 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.13 |
| Education | $132.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,061.35 | 2019-2022 | |
| Alkermes, INC. | $636.03 | 2019-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $590.47 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $489.48 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $437.49 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $429.04 | 2019-2025 | Invega Sustenna |
| Indivior INC. | $238.19 | 2019-2024 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $217.36 | 2019-2023 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $201.19 | 2020-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $165.75 | 2022-2025 | Austedo, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $145.17 | 2024-2025 | Cobenfy |
| Corium, LLC | $114.18 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $99.98 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $99.71 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Neurocrine Biosciences, INC. | $96.54 | 2019-2025 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $89.10 | 2023-2024 | Auvelity |
| Shire North American Group INC | $75.23 | 2019 | |
| Avanir Pharmaceuticals, INC. | $61.91 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $43.63 | 2019 | |
| Acadia Pharmaceuticals INC | $23.87 | 2023 | Nuplazid |
| Eisai INC. | $21.92 | 2021 | |
| Merck Sharp & Dohme LLC | $18.72 | 2020 | |
| Vertical Pharmaceuticals, LLC | $16.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Vandenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.